This contract expires in 265 days (Jan 15, 2027).
NKA BIO, INC - ANTI-SHOCK INJECTION TO IMPROVE COMBAT CASUALTY CARE
Key Details
Description
ANTI-SHOCK INJECTION TO IMPROVE COMBAT CASUALTY CARE
Context & Analysis
On Nov 18, 2025, Department of Defense obligated $1,245,837 to NKA BIO, INC for anti-shock injection to improve combat casualty care. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition after exclusion of sources with 115 offers received. The procurement used a SMALL BUSINESS SET ASIDE - TOTAL set-aside. Performance is located in BALTIMORE, MD. The contract is scheduled through Jan 15, 2027 — approximately 9 months remaining. This award is one of several similar procurements from Department of Defense under NAICS 541715 — related awards are listed below.
Contractor Information
Similar Awards
NAVAL NUCLEAR LABORATORY
FLUOR MARINE PROPULSION, LLC
$14.2B
NAVAL NUCLEAR LABORATORY
FLUOR MARINE PROPULSION, LLC
$13.6B
NEXT GENERATION OVERHEAD PERSISTENT INFRARED GEOSYNCHRONOUS EARTH ORBIT SPACE VEHICLE 1-3 PHASE 1
LOCKHEED MARTIN CORP
$6.3B
NEXT GENERATION OVERHEAD PERSISTENT INFRARED GEOSYNCHRONOUS EARTH ORBIT SPACE VEHICLE 1-3 PHASE 1
LOCKHEED MARTIN CORP
$6.3B
DESIGN, DEVELOPMENT, AND DEVELOPMENTAL TESTING OF THE NEXT GENERATION INTERCEPTOR (NGI) ALL-UP-ROUND (AUR)
LOCKHEED MARTIN CORPORATION
$4.6B
Stay Updated
Get notified about new opportunities matching your interests.